{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:27:27Z","timestamp":1792106847045,"version":"4.4.0"},"reference-count":149,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2016,1,15]],"date-time":"2016-01-15T00:00:00Z","timestamp":1452816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>The association of autoantibodies to cytokines with immune deficiency, autoimmunity and\/or immune dysregulation is increasingly being recognized. For example, autoantibodies to interferon gamma have been found to be associated with chronic, treatment refractory infections with intracellular organisms such as mycobacteria, autoantibodies to interleukin 17 with chronic mucocutaneous candidiasis, and anti-interferon alpha autoantibodies with systemic lupus erythematosus. While low titer autoantibodies to these and other cytokines may be detected in normal individuals, patients with infectious or autoimmune manifestations tend to have high titer autoantibodies that may block or potentiate the function of the respective cytokine. Recognition of these autoantibodies is important because it may direct treatment toward a combination of adjunctive immunotherapy to modulate the autoantibody level while continuing with appropriate anti-microbial therapy. This review focuses on the anti-cytokine autoantibodies documented to date, their autoimmune, immune dysregulation and infectious disease associations, methods for detection of these antibodies and potential treatment options.<\/jats:p>","DOI":"10.3390\/antib5010003","type":"journal-article","created":{"date-parts":[[2016,1,16]],"date-time":"2016-01-16T03:30:25Z","timestamp":1452915025000},"page":"3","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Anticytokine Autoantibodies: Association with Infection and Immune Dysregulation"],"prefix":"10.3390","volume":"5","author":[{"given":"Vijaya","family":"Knight","sequence":"first","affiliation":[{"name":"Division of Pathology, Department of Medicine, National Jewish Health, Denver, CO 80015, USA"},{"name":"National Jewish Health Advanced Diagnostic Laboratories, National Jewish Health, Denver, CO 80015, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4594-725X","authenticated-orcid":false,"given":"Patricia","family":"Merkel","sequence":"additional","affiliation":[{"name":"Division of Pathology, Department of Medicine, National Jewish Health, Denver, CO 80015, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O\u2019Sullivan","sequence":"additional","affiliation":[{"name":"Immunology Department, PathWest Laboratory Medicine WA, Perth 6009, Australia"},{"name":"School of Pathology and Laboratory Medicine, University of Western Australia, Perth 6009, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,1,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1146\/annurev-immunol-032713-120222","article-title":"Anticytokine autoantibody-associated immunodeficiency","volume":"32","author":"Browne","year":"2014","journal-title":"Ann. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1473-3099(10)70196-1","article-title":"Anticytokine autoantibodies in infectious diseases: Pathogenesis and mechanisms","volume":"10","author":"Browne","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/ACI.0b013e3283402b41","article-title":"Immunodeficiency secondary to anticytokine autoantibodies","volume":"10","author":"Browne","year":"2010","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","article-title":"Cellular responses to interferon-gamma","volume":"15","author":"Boehm","year":"1997","journal-title":"Ann. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1074-7613(01)00218-7","article-title":"GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1","volume":"15","author":"Shibata","year":"2001","journal-title":"Immunity"},{"key":"ref_6","first-page":"L1132","article-title":"PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor","volume":"285","author":"Bonfield","year":"2003","journal-title":"Am. J. Physiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/art.10497","article-title":"Autoantibodies against granulocyte colony-stimulating factor in Felty\u2019s syndrome and neutropenic systemic lupus erythematosus","volume":"46","author":"Hellmich","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1016\/j.febslet.2007.04.029","article-title":"Anti-cytokine autoantibodies are ubiquitous in healthy individuals","volume":"581","author":"Watanabe","year":"2007","journal-title":"FEBS Lett."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1365-2567.2000.00949.x","article-title":"Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations","volume":"99","author":"Wadhwa","year":"2000","journal-title":"Immunology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0162-3109(94)90058-2","article-title":"An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2","volume":"28","author":"Courtney","year":"1994","journal-title":"Immunopharmacology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1182\/blood-2003-05-1565","article-title":"High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis","volume":"103","author":"Uchida","year":"2004","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Nagele, E.P., Han, M., Acharya, N.K., DeMarshall, C., Kosciuk, M.C., and Nagele, R.G. (2013). Natural IgG autoantibodies are abundant and ubiquitous in human sera, and their number is influenced by age, gender, and disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060726"},{"key":"ref_13","first-page":"136","article-title":"Anti-cytokine autoantibodies in autoimmune diseases","volume":"1","author":"Cappellano","year":"2012","journal-title":"Am. J. Clin. Exp. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s10875-013-9938-6","article-title":"Anti-cytokine autoantibodies preceding onset of autoimmune polyendocrine syndrome type I features in early childhood","volume":"33","author":"Wolff","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1056\/NEJMc0904077","article-title":"Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis","volume":"361","author":"Sakagami","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1093\/cid\/cit809","article-title":"Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-gamma autoantibody","volume":"58","author":"Czaja","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Piccoli, L., Campo, I., Fregni, C.S., Rodriguez, B.M., Minola, A., Sallusto, F., Luisetti, M., Corti, D., and Lanzavecchia, A. (2015). Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis. Nat. Commun., 6.","DOI":"10.1038\/ncomms8375"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Rosenberg, J.M., Price, J.V., Barcenas-Morales, G., Ceron-Gutierrez, L., Davies, S., Kumararatne, D.S., Doffinger, R., and Utz, P.J. (2015). Protein microarrays identify disease-specific anti-cytokine autoantibody profiles in the landscape of immunodeficiency. J. Allergy Clin. Immunol.","DOI":"10.1016\/j.jaci.2015.07.032"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ching, K.H., Burbelo, P.D., Tipton, C., Wei, C., Petri, M., Sanz, I., and Iadarola, M.J. (2012). Two major autoantibody clusters in systemic lupus erythematosus. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0032001"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1172\/JCI80477","article-title":"Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency","volume":"125","author":"Walter","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-3083.1997.d01-139.x","article-title":"High levels of neutralizing autoantibodies against IL-1 alpha are associated with a better prognosis in chronic polyarthritis: A follow-up study","volume":"46","author":"Jouvenne","year":"1997","journal-title":"Scand. J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"140. Mizutani, H., Ohmoto, Y., Kupper, T.S., and Shimizu, M. (1998). Endogenous neutralizing anti-IL-1 alpha autoantibodies in inflammatory skin diseases: Possible natural inhibitor for over expressed epidermal IL-1. J. Dermatol. Sci., 20, 63\u201371.","DOI":"10.1016\/S0923-1811(98)00074-7"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4049\/jimmunol.180.1.647","article-title":"Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6","volume":"180","author":"Puel","year":"2008","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/art.1780350814","article-title":"Anti-interleukin-6 autoantibodies in rheumatic diseases. Increased frequency in the sera of patients with systemic sclerosis","volume":"35","author":"Takemura","year":"1992","journal-title":"Arthritis Rheum."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.4049\/jimmunol.152.2.935","article-title":"IL-6-anti-IL-6 autoantibody complexes with IL-6 activity in sera from some patients with systemic sclerosis","volume":"152","author":"Suzuki","year":"1994","journal-title":"J. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/annrheumdis-2012-202768","article-title":"Suppression of elevations in serum C reactive protein levels by anti-IL-6 autoantibodies in two patients with severe bacterial infections","volume":"72","author":"Nanki","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1042\/CS20070272","article-title":"Anti-interleukin-8 autoantibody:interleukin-8 immune complexes in acute lung injury\/acute respiratory distress syndrome","volume":"114","author":"Fudala","year":"2008","journal-title":"Clin. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/S0140-6736(05)64012-3","article-title":"Spontaneous neutralising antibodies to interferon--alpha and interleukin-12 in thymoma-associated autoimmune disease","volume":"350","author":"Meager","year":"1997","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s10875-013-9908-z","article-title":"Recurrent Burkholderia gladioli suppurative lymphadenitis associated with neutralizing anti-IL-12p70 autoantibodies","volume":"33","author":"Sim","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1084\/jem.20091983","article-title":"Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I","volume":"207","author":"Puel","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.4049\/jimmunol.1202526","article-title":"Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis","volume":"190","author":"Rosen","year":"2013","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/cid\/ciu968","article-title":"Nocardia-induced granulocyte macrophage colony-stimulating factor is neutralized by autoantibodies in disseminated\/extrapulmonary nocardiosis","volume":"60","author":"Rosen","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.58.3.252","article-title":"Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis","volume":"58","author":"Seymour","year":"2003","journal-title":"Thorax"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa062505","article-title":"GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis","volume":"356","author":"Uchida","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_36","first-page":"15","article-title":"Mycobacterium avium complex empyema in a patient with interferon gamma autoantibodies","volume":"73","author":"DeLeon","year":"2014","journal-title":"Hawai\u2019i J. Med. Public Health"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10875-015-0161-5","article-title":"Salmonella Sepsis in a German Caucasian Patient with Unusual Anti-Interferon-Gamma IgG1 Autoantibodies","volume":"35","author":"Hanitsch","year":"2015","journal-title":"J. Clin. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1086\/605581","article-title":"Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-gamma autoantibody","volume":"49","author":"Baerlecken","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/art.30399","article-title":"Association of endogenous anti-interferon-alpha autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus","volume":"63","author":"Morimoto","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/intimm\/dxg088","article-title":"Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor","volume":"15","author":"Shiono","year":"2003","journal-title":"Int. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1172\/JCI70231","article-title":"Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus","volume":"123","author":"Price","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_42","first-page":"1492","article-title":"Autoantibodies to osteopontin in patients with osteoarthritis and rheumatoid arthritis","volume":"28","author":"Sakata","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3892\/or.2014.3367","article-title":"Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma","volume":"32","author":"Ying","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jaut.2004.02.003","article-title":"Reduced anti-TNFalpha autoantibody levels coincide with flare in systemic lupus erythematosus","volume":"22","author":"Sjowall","year":"2004","journal-title":"J. Autoimmun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2362.1998.00279.x","article-title":"Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke","volume":"28","author":"Elkarim","year":"1998","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/annrheumdis-2014-207219","article-title":"Autoantibodies to osteoprotegerin are associated with increased bone resorption in rheumatoid arthritis","volume":"74","author":"Hauser","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00223-015-0023-4","article-title":"Characterisation of osteoprotegerin autoantibodies in coeliac disease","volume":"97","author":"Real","year":"2015","journal-title":"Calcified Tissue Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1056\/NEJMoa0810925","article-title":"Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin","volume":"361","author":"Riches","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1359-6101(00)00010-1","article-title":"Interferon-gamma and interleukin-12 pathway defects and human disease","volume":"11","author":"Dorman","year":"2000","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-gamma: An overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J. Leuk. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.4049\/jimmunol.163.9.4647","article-title":"Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells","volume":"163","author":"Carnaud","year":"1999","journal-title":"J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1359-6101(98)00007-0","article-title":"IFN-gamma expression in macrophages and its possible biological significance","volume":"9","author":"Gessani","year":"1998","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/82717","article-title":"Reciprocal regulation of polarized cytokine production by effector B and T cells","volume":"1","author":"Harris","year":"2000","journal-title":"Nat. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1203\/00006450-200107000-00005","article-title":"Impaired interferon gamma-mediated immunity and susceptibility to mycobacterial infection in childhood","volume":"50","author":"Remus","year":"2001","journal-title":"Pediatr. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0272-5231(02)00012-6","article-title":"Pathogenesis of nontuberculous mycobacteria infections","volume":"23","author":"McGarvey","year":"2002","journal-title":"Clin. Chest Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1086\/380453","article-title":"Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity","volume":"38","author":"Doffinger","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2012-08-452482","article-title":"Anti-IFN-gamma autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection","volume":"121","author":"Chi","year":"2013","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/JCM.03339-14","article-title":"Recurrence of disseminated Mycobacterium avium complex disease in a patient with anti-gamma interferon autoantibodies by reinfection","volume":"53","author":"Nishimura","year":"2015","journal-title":"J. Clin. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s10875-014-0073-9","article-title":"The first US domestic report of disseminated Mycobacterium avium complex and anti-interferon-gamma autoantibodies","volume":"34","author":"Rosen","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.4049\/jimmunol.175.7.4769","article-title":"Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections","volume":"175","author":"Patel","year":"2005","journal-title":"J. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/pathogens4030606","article-title":"Interleukin 17-Mediated Host Defense against Candida albicans","volume":"4","author":"Sparber","year":"2015","journal-title":"Pathogens"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23-IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/imr.12027","article-title":"IL-22, not simply a Th17 cytokine","volume":"252","author":"Rutz","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00006454-200102000-00017","article-title":"Chronic mucocutaneous candidiasis","volume":"20","author":"Kirkpatrick","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00001432-200204000-00007","article-title":"New perspectives on the immunology of chronic mucocutaneous candidiasis","volume":"15","author":"Lilic","year":"2002","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nature06764","article-title":"Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome","volume":"452","author":"Milner","year":"2008","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1056\/NEJMoa0810719","article-title":"A homozygous CARD9 mutation in a family with susceptibility to fungal infections","volume":"361","author":"Glocker","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1056\/NEJMoa0901053","article-title":"Human dectin-1 deficiency and mucocutaneous fungal infections","volume":"361","author":"Ferwerda","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/ACI.0b013e328358cc0b","article-title":"Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis","volume":"12","author":"Puel","year":"2012","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Thorpe, E.S., and Handley, H.E. (1929). Chronic tetany and chronic mycelia stomatitis in a child aged four and one half years. Am. J. Dis. Child., 38.","DOI":"10.1001\/archpedi.1929.01930080104011"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1056\/NEJM199006283222601","article-title":"Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients","volume":"322","author":"Ahonen","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ng1297-399","article-title":"An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains","volume":"17","year":"1997","journal-title":"Nat. Genet."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/path.2141","article-title":"Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1)","volume":"211","author":"Strobel","year":"2007","journal-title":"J. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.V68.3.708.708","article-title":"Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils","volume":"68","author":"Fleischmann","year":"1986","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.8171324","article-title":"Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis","volume":"264","author":"Dranoff","year":"1994","journal-title":"Science"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1073\/pnas.91.12.5592","article-title":"Granulocyte\/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology","volume":"91","author":"Stanley","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"L379","DOI":"10.1152\/ajplung.2001.280.3.L379","article-title":"GM-CSF regulates protein and lipid catabolism by alveolar macrophages","volume":"280","author":"Yoshida","year":"2001","journal-title":"Am. J. Physiol. Lung C."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1056\/NEJMra023226","article-title":"Pulmonary alveolar proteinosis","volume":"349","author":"Trapnell","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM195806052582301","article-title":"Pulmonary alveolar proteinosis","volume":"258","author":"Rosen","year":"1958","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1084\/jem.190.6.875","article-title":"Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte\/macrophage colony-stimulating factor","volume":"190","author":"Kitamura","year":"1999","journal-title":"J. Exp. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/ajrccm.161.4.9906080","article-title":"Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis","volume":"161","author":"Carraway","year":"2000","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1006\/clim.2002.5301","article-title":"Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis","volume":"105","author":"Bonfield","year":"2002","journal-title":"Clin. Immunol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-85-3-304","article-title":"Defective lung macrophages in pulmonary alveolar proteinosis","volume":"85","author":"Golde","year":"1976","journal-title":"Ann. Int. Med."},{"key":"ref_87","first-page":"656","article-title":"Pulmonary alveolar proteinosis. Further evaluation of abnormal alveolar macrophages","volume":"90","author":"Harris","year":"1986","journal-title":"Chest"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1164\/rccm.2109105","article-title":"Pulmonary alveolar proteinosis: Progress in the first 44 years","volume":"166","author":"Seymour","year":"2002","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1136\/annrheumdis-2013-204816","article-title":"MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: Results of a phase Ib\/IIa randomised, double-blind, placebo-controlled, dose-escalation trial","volume":"74","author":"Behrens","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/pro.5560060501","article-title":"Interleukin-6: Structure-function relationships","volume":"6","author":"Simpson","year":"1997","journal-title":"Protein Sci."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Cooper, C.J., Said, S., and Hernandez, G.T. (2014). Recurrent Skin and Lung Infections in Autosomal Dominant Hyper IgE Syndrome with Transactivation Domain STAT3 Mutation. Case Rep. Immunol., 2014.","DOI":"10.1155\/2014\/136752"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1046\/j.1365-3083.1996.d01-344.x","article-title":"Anti-interleukin-6 autoantibodies in plasma are associated with an increased frequency of infections and increased mortality of patients with alcoholic cirrhosis","volume":"44","author":"Homann","year":"1996","journal-title":"Scand. J. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.smim.2014.01.009","article-title":"A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy","volume":"26","author":"Tanaka","year":"2014","journal-title":"Semin. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/intimm\/dxu081","article-title":"Therapeutic uses of anti-interleukin-6 receptor antibody","volume":"27","author":"Kang","year":"2015","journal-title":"Int. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Tedesco, S., Postacchini, L., Manfredi, L., Goteri, G., Luchetti, M.M., Festa, A., Gabrielli, A., and Pomponio, G. (2015). Successful treatment of a Caucasian case of multifocal Castleman\u2019s disease with TAFRO syndrome with a pathophysiology targeted therapy\u2014A case report. Exp. Hematol. Oncol., 4.","DOI":"10.1186\/2162-3619-4-3"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Longterm Safety of Tocilizumab: Results from 3 Years of Followup Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J. Rheumatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11926-015-0542-z","article-title":"Biologic-Associated Infections in Pediatric Rheumatology","volume":"17","author":"Horneff","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"P. Roy. Soc. Lond. B Bio."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nri1684","article-title":"The yin and yang of type I interferon activity in bacterial infection","volume":"5","author":"Decker","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: Friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1084\/jem.185.5.921","article-title":"Crucial role of interferon consensus sequence binding protein, but neither of interferon regulatory factor 1 nor of nitric oxide synthesis for protection against murine listeriosis","volume":"185","author":"Fehr","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1073\/pnas.091096998","article-title":"Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha \/beta","volume":"98","author":"Manca","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197907053010102","article-title":"Immune interferon in the circulation of patients with autoimmune disease","volume":"301","author":"Hooks","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/art.1780250407","article-title":"Serum interferon levels in patients with systemic lupus erythematosus","volume":"25","author":"Ytterberg","year":"1982","journal-title":"Arthritis Rheum."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7326\/0003-4819-115-3-178","article-title":"Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors","volume":"115","author":"Ronnblom","year":"1991","journal-title":"Ann. Int. Med."},{"key":"ref_107","unstructured":"Sanchez Roman, J., Castillo Palma, M.J., Garcia Diaz, E., and Ferrer Ordinez, J.A. (1994). Systemic lupus erythematosus induced by recombinant alpha interferon treatment. Med. Clin., 102."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","article-title":"Interferon and granulopoiesis signatures in systemic lupus erythematosus blood","volume":"197","author":"Bennett","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00043426-199124000-00004","article-title":"Human granulocyte colony-stimulating factor: Its basic aspects and clinical applications","volume":"13","author":"Asano","year":"1991","journal-title":"Am. J. Pediatr. Hematol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1182\/blood.V84.6.1737.1737","article-title":"Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization","volume":"84","author":"Lieschke","year":"1994","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1074-7613(00)80504-X","article-title":"Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice","volume":"5","author":"Liu","year":"1996","journal-title":"Immunity"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1126\/science.1718038","article-title":"Regulation of transendothelial neutrophil migration by endogenous interleukin-8","volume":"254","author":"Huber","year":"1991","journal-title":"Science"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1021\/bi00459a004","article-title":"Three-dimensional structure of interleukin 8 in solution","volume":"29","author":"Clore","year":"1990","journal-title":"Biochemistry"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI114265","article-title":"Neutrophil-activating peptide-1\/interleukin 8, a novel cytokine that activates neutrophils","volume":"84","author":"Baggiolini","year":"1989","journal-title":"J. Clin. Investig."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1084\/jem.171.4.1155","article-title":"Neutrophil-activating protein 1\/interleukin 8 stimulates the binding activity of the leukocyte adhesion receptor CD11b\/CD18 on human neutrophils","volume":"171","author":"Detmers","year":"1990","journal-title":"J. Exp. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1084\/jem.171.5.1797","article-title":"Neutrophil-activating properties of the melanoma growth-stimulatory activity","volume":"171","author":"Moser","year":"1990","journal-title":"J. Exp. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0006-291X(90)91929-M","article-title":"NAP-1\/IL-8 induces up-regulation of CR1 receptors in human neutrophil leukocytes","volume":"166","author":"Paccaud","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(67)90168-7","article-title":"Acute respiratory distress in adults","volume":"2","author":"Ashbaugh","year":"1967","journal-title":"Lancet"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"L364","DOI":"10.1152\/ajplung.00179.2006","article-title":"Anti-IL-8 autoantibody:IL-8 immune complexes suppress spontaneous apoptosis of neutrophils","volume":"293","author":"Fudala","year":"2007","journal-title":"Am. J. Physiol. Lung C."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2007.06492.x","article-title":"The pathogenesis of transfusion-related acute lung injury (TRALI)","volume":"136","author":"Bux","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Triulzi, D.J. (2006). Transfusion-related acute lung injury: An update. Hematology, 497\u2013501.","DOI":"10.1182\/asheducation-2006.1.497"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1258\/ebm.2010.010137","article-title":"Landmark advances in the development of erythropoietin","volume":"235","author":"Fisher","year":"2010","journal-title":"Exp. Biol. Med."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"H\u00f6ke, A. (2006). Erythropoietin and the Nervous System, Springer.","DOI":"10.1007\/978-0-387-30011-5"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1182\/blood-2014-11-575357","article-title":"Emerging EPO and EPO receptor regulators and signal transducers","volume":"125","author":"Kuhrt","year":"2015","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/brainsci5020165","article-title":"Growth factors for the treatment of ischemic brain injury (growth factor treatment)","volume":"5","author":"Larpthaveesarp","year":"2015","journal-title":"Brain Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.drudis.2015.09.001","article-title":"Neuroprotective agents for neonatal hypoxic-ischemic brain injury","volume":"20","author":"Wu","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.clp.2015.04.004","article-title":"Erythropoietin and Neonatal Neuroprotection","volume":"42","author":"Juul","year":"2015","journal-title":"Clin. Perinatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/ki.2011.500","article-title":"Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: New insights","volume":"81","author":"Macdougall","year":"2012","journal-title":"Kidney Int."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2215\/CJN.02440607","article-title":"Pure red cell aplasia induced by erythropoiesis-stimulating agents","volume":"3","author":"Pollock","year":"2008","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/ndt\/gfg182","article-title":"Pure red-cell aplasia due to anti-erythropoietin antibodies","volume":"18","author":"Eckardt","year":"2003","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJM199603073341004","article-title":"Autoantibodies against erythropoietin in a patient with pure red-cell aplasia","volume":"334","author":"Casadevall","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.1975.tb01855.x","article-title":"Pure red cell aplasia: Studies on an IgG serum inhibitor neutralizing erythropoietin","volume":"30","author":"Peschle","year":"1975","journal-title":"Br. J. Haematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/03009749950154293","article-title":"Pure red cell aplasia as presentation of systemic lupus erythematosus: Antibodies to erythropoietin","volume":"28","author":"Linardaki","year":"1999","journal-title":"Scand. J. Rheumatol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"viii37","DOI":"10.1093\/ndt\/gfg1091","article-title":"Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin","volume":"18","author":"Casadevall","year":"2003","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/01.ASN.0000107561.59698.42","article-title":"Anti-erythropoietin antibodies and pure red cell aplasia","volume":"15","author":"Rossert","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/ki.2011.45","article-title":"Erythropoiesis-stimulating agents and pure red-cell aplasia: You can\u2019t fool Mother Nature","volume":"80","author":"Wish","year":"2011","journal-title":"Kidney Int."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S1473-3099(15)00089-4","article-title":"Host susceptibility to non-tuberculous mycobacterial infections","volume":"15","author":"Wu","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1164\/ajrccm.163.2.2003146","article-title":"Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis","volume":"163","author":"Seymour","year":"2001","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1378\/chest.130.1.227","article-title":"An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis","volume":"130","author":"Venkateshiah","year":"2006","journal-title":"Chest"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1164\/rccm.200906-0978OC","article-title":"Inhaled granulocyte\/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis","volume":"181","author":"Tazawa","year":"2010","journal-title":"Am. J. Resp. Crit. Care Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1538-7836.2011.04349.x","article-title":"Immune tolerance induction in haemophilia: Evidence and the way forward","volume":"9","year":"2011","journal-title":"J. Thromb. Haemost."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Akasaka, K., Tanaka, T., Kitamura, N., Ohkouchi, S., Tazawa, R., Takada, T., Ichiwata, T., Yamaguchi, E., Hirose, M., and Arai, T. (2015). Outcome of corticosteroid administration in autoimmune pulmonary alveolar proteinosis: A retrospective cohort study. BMC Pulm. Med., 15.","DOI":"10.1186\/s12890-015-0085-0"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1165\/rcmb.2002-0023OC","article-title":"Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis","volume":"27","author":"Bonfield","year":"2002","journal-title":"Am. J. Resp. Cell Mol. Biol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1183\/09031936.00097508","article-title":"Plasmapheresis for treatment of pulmonary alveolar proteinosis","volume":"33","author":"Luisetti","year":"2009","journal-title":"Eur. Resp. J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1183\/09031936.00197710","article-title":"An open-label trial of rituximab therapy in pulmonary alveolar proteinosis","volume":"38","author":"Kavuru","year":"2011","journal-title":"Eur. Resp. J."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1182\/blood-2011-12-395707","article-title":"Anti-CD20 (rituximab) therapy for anti-IFN-gamma autoantibody-associated nontuberculous mycobacterial infection","volume":"119","author":"Browne","year":"2012","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Behler, C.M., Terrault, N.A., Etzell, J.E., and Damon, L.E. (2009). Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: A case report. J. Med. Case Rep., 3.","DOI":"10.4076\/1752-1947-3-7335"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/5\/1\/3\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:17:48Z","timestamp":1760210268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/5\/1\/3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,15]]},"references-count":149,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,3]]}},"alternative-id":["antib5010003"],"URL":"https:\/\/doi.org\/10.3390\/antib5010003","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,15]]}}}